WithdrawnNot Applicable

Incidence and Associated Risk Factors of ARC in the Trauma Critically Ill Older Than 50 Years Old

Stopped: This study was planned and approved just before the 2020 pandemic - once the pandemic resolved, significant changes occurred in the ICU that prevented doing the study - hence it was withdrawn with no patient ever enrolled

Canada0Started 2024-03

Plain-language summary

This single-center prospective cohort study conducted at the adult trauma ICU of the Montreal General Hospital (MGH) affiliated with the McGill University Health Centre (MUHC) aims to determine the incidence and associated risk factors of augmented renal clearance (ARC) in critically ill trauma patients of 50 years old and above.

Who can participate

Age range

50 Years

Sex

ALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion Criteria: * Admission to the ICU for isolated traumatic brain injury (TBI), polytrauma without TBI or combined polytrauma and TBI * Expected ICU length of stay of more than 24 hours * Age of ≥ 50 years old at the time of admission * Serum creatinine ≤ 120 μmol/L at the time of admission * Presence of an indwelling urinary catheter * Consent is obtained from the patient or its surrogate decision-maker within 7 days of ICU admission Exclusion Criteria: * History of renal replacement therapy (RRT) (intermittent dialysis or peritoneal dialysis), nephrectomy or renal transplant * Patient developing acute kidney injury (AKI) * ICU physician considered patient unsuitable for enrollment due to poor prognosis * Burn-related trauma * Patient is admitted \> 48 hours post-traumatic event

Questions worth asking your doctor

Bring these to your next appointment. They're a starting point for a shared conversation — not a sign you qualify or a recommendation to enrol.

1Based on my diagnosis and history, is this trial worth exploring for me — or is there a standard treatment we should try first?
2What does this trial's phase tell us about how much is already known about its safety and benefit?
3What would taking part actually involve for me — visits, tests, time, and travel?
4What are the known and possible risks or side effects I should weigh, and how would they be monitored?
5If this trial isn't the right fit, what other options or trials would you suggest I look into?

Generated to help you prepare — always confirm anything about your own eligibility and care with the study team and your doctor.

Questions for the trial coordinator

The trial coordinator is the person who runs the study day to day. These cover the practical side — logistics, costs, and what taking part would actually mean for your life. The study team confirms whether you meet the criteria; these are questions to ask, not a sign you qualify.

1What does taking part actually involve week to week — how many visits, where, and how long does each one take?
2What costs are covered by the study, and what might I have to pay for myself, including travel, parking, or time off work?
3What happens during screening, and what happens if the study team confirms I don't meet the criteria after those tests?
4Who pays for the scans, blood work, and other tests the trial requires — the study, my insurance, or me?
5How will being in the trial affect my regular care, and will my own doctor stay informed and involved?
6Can I leave the trial at any point if I change my mind, and what would happen to my care if I do?

A starting point for the conversation — always confirm anything about your own eligibility, costs, and care with the study team and your doctor.

What they're measuring

To determine the incidence of augmented renal clearance in critically ill trauma patients aged 50 years and older

Timeframe: Once a day, up to 14 days

Trial details

NCT IDNCT04766944

SponsorMcGill University Health Centre/Research Institute of the McGill University Health Centre

Sponsor typeOTHER

Study typeOBSERVATIONAL

Primary completion2024-12

View on ClinicalTrials.gov More Augmented Renal Clearance trials